Pixel Pandemonium is a new exhibit, organised by the ESR and EIBIR and endorsed by MICCAI. It offers an great platform for showcasing the latest AI
Today, September 11th, 2024, our Scientific Coordinator took the spotlight at the EUCAIM and ESR webinar, “How to Advance Precision Medicine for Europe’s Cancer Patients
The CHAIMELEON Re-Identification Challenge, which aims to test the effectiveness of de-identification processes in AI-driven health projects, has extended its registration deadline to September 30, 2024.
Open Call applicants’ Guide to required legal and ethical documents: Table of Contents The EUCAIM open call was closed on the 10th of June. The
EUCAIM’s first 18 months have been remarkable! 🤩 We are thrilled to announce the release of our latest newsletter, showcasing the key achievements and offering
We would like to inform you that the European Commission has launched an open stakeholder consultation on the Digital Europe Programme (DIGITAL), as part of
We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.
Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.
Apply by 10 June 2024!
We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.
EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.
Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.
Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.